Cardinal Health Inc SEC Filings

Gaxos.ai Inc. (ticker GXAI) has issued its Definitive Proxy Statement for the 2025 Annual Meeting, scheduled for 9:00 a.m. ET on August 12, 2025 at the company’s Roseland, NJ headquarters. Shareholders of record as of June 20, 2025 (7,123,453 common shares outstanding) may vote by Internet, mail, phone or in person. A quorum requires 33⅓ % (2,374,482 shares) of the outstanding stock.

Key items up for vote:

• Proposal 1 – Election of four directors (Vadim Mats, Adam Holzer, Scott A. Grayson, Roman Feldman) for one-year terms ending at the 2026 meeting.
• Proposal 2 – Auditor ratification: Salberg & Company, P.A. to remain independent registered public accounting firm for FY 2025. 2024 audit fee: $67,000; total 2024 fees: $78,000.
• Proposal 3 – Equity Plan Amendment: increase shares reserved under the 2022 Omnibus Equity Incentive Plan to 803,637 from 553,637 (additional 250,000 shares ≈ 3.5 % dilution of current outstanding shares). As of the record date, 414,553 shares remain available for issuance.

The Board, comprising three independent directors, unanimously recommends “FOR” all three proposals. Compensation highlights: non-employee directors each received $24,000 cash plus options valued at $11,293 (exercise $6.00, vest 3/5/2025). CEO Vadim Mats earned $400,000 salary and $150,000 bonus in 2024; CFO Steven A. Shorr earned $60,000.

Governance notes: majority-independent board; combined CEO/Chair role; established Audit, Compensation and Nominating/Governance committees; insider-trading and anti-hedging policies in force. No related-party transactions above disclosure thresholds; no appraisal rights are available for the current proposals.

Cardinal Health, Inc. (CAH) filed a Form 4 indicating that Chief Executive Officer Jason M. Hollar had 5,821 common shares automatically withheld on 06/30/2025 to cover tax obligations arising from the deferred settlement of previously awarded performance share units (transaction code “F”). The price recorded for the withholding was $167.18 per share, representing an aggregate value of roughly $0.97 million. After the transaction, Hollar’s direct ownership stands at 191,815 shares.

This is an administrative, non-open-market transaction. No shares were purchased or sold for investment purposes, and there is no indication of a change in the CEO’s long-term stake. The filing therefore carries minimal fundamental or market impact, serving primarily to update compliance records under Section 16(a).

Effective June 30, 2025, the Statement of Additional Information (SAI) for John Hancock Financial Opportunities Fund (ticker BTO), John Hancock Investors Trust and John Hancock Premium Dividend Fund is updated to reflect two governance changes:

• Paul Lorentz has resigned as a non-independent Trustee of each fund.
• Kristie M. Feinberg, already serving as each fund’s President and CEO of John Hancock Investment Management, has been appointed as a non-independent Trustee effective the same date and will stand for shareholder election in 2026.

The SAI now lists Ms. Feinberg’s extensive leadership background, including her roles at Manulife Investment Management, Invesco and Oppenheimer Funds, underscoring her experience in finance, strategy and product distribution. The board-class assignment for the Financial Opportunities Fund and Premium Dividend Fund places her term expiring in 2026. The John Hancock Fund Complex comprises 186 funds as of April 30, 2025.

No portfolio, financial or strategic policy changes are disclosed; the supplement is solely a board-composition update, to be read in conjunction with the current SAI.